Get the Stockscreener App
3.44
2.27%
-0.08
After Hours:
3.60
0.16
+4.65%
Oramed Pharmaceuticals Inc stock is traded at $3.44, with a volume of 230.08K.
It is down -2.27% in the last 24 hours and up +17.41% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$3.52
Open:
$3.49
24h Volume:
230.08K
Relative Volume:
1.02
Market Cap:
$136.92M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
31.27
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
-5.49%
1M Performance:
+17.41%
6M Performance:
+62.26%
1Y Performance:
+49.57%
1-Day Range:
$3.43
$3.65
1-Week Range:
$3.35
$3.71
52-Week Range:
$1.82
$3.71
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.44 | 140.10M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.14 | 112.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.33 | 77.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.37 | 50.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
365.46 | 46.97B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.64 | 36.99B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Is Oramed Pharmaceuticals Inc. stock undervalued right nowVolume Analysis Techniques & Plan Every Trade With Controlled Risk - bollywoodhelpline.com
What hedge funds are buying Oramed Pharmaceuticals Inc.Recession Risk & Daily Technical Forecast Reports - bollywoodhelpline.com
Published on: 2026-01-17 10:34:33 - baoquankhu1.vn
Oramed Pharmaceuticals Inc.: - marketscreener.com
Oramed Pharm pivots with Lifeward strategic platform deal - TipRanks
Oramed Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Oramed to transfer oral drug delivery platform to Lifeward By Investing.com - Investing.com Nigeria
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal - Investing.com Nigeria
Buyout Rumor: Can Oramed Pharmaceuticals Inc maintain sales growthQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Oramed And Lifeward Reveal Strategic Deal - Pulse 2.0
Oramed to transfer oral drug delivery platform to Lifeward - Investing.com India
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - manilatimes.net
Oramed and Lifeward Announce Strategic Transaction - Nasdaq
Lifeward Ltd. announced that it expects to receive $20 million in funding from Oramed Pharmaceuticals Inc. - marketscreener.com
Oramed Announces Shareholder Capital Return Following Strategic Windfall - AD HOC NEWS
Take Profit: Will Oramed Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Intraday Action & Growth Focused Investment Plans - Улправда
Why Oramed Pharmaceuticals Inc. stock could outperform in 2025Trade Performance Summary & Risk Managed Investment Entry Signals - Улправда
Is Oramed Pharmaceuticals Inc. stock a buy in volatile markets2025 Retail Activity & Daily Volume Surge Signals - ulpravda.ru
Will Oramed Pharmaceuticals Inc. stock outperform value stocks2025 Key Lessons & Intraday High Probability Alerts - ulpravda.ru
Oramed Pharmaceuticals Inc. Declares Dividend of $0.25 (NASDAQ:ORMP) - MarketBeat
Oramed inks deal with Medicox for oral insulin in South Korea - The Pharma Letter
Is Oramed Pharmaceuticals Inc. (OJU1) stock suitable for passive index fundsMarket Sentiment Shifts & Outstanding Capital Returns - Улправда
MSN Money - MSN
Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026 - MarketScreener
Oramed stock rises after receiving $18 million payment from Scilex By Investing.com - Investing.com Nigeria
Oramed receives $18 million payment from Scilex, declares dividend By Investing.com - Investing.com Nigeria
Oramed Pharm Announces Dividend After Scilex Payment Gain - TipRanks
Oramed receives $18 million payment from Scilex, declares dividend - Investing.com
Oramed Pharmaceuticals Inc Receives $18 Million Payment and Approves Dividend - TradingView — Track All Markets
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - Barchart.com
What analysts say about Oramed Pharmaceuticals Inc stockLow Beta Stocks & Breakthrough Profit Margins - earlytimes.in
Oramed Pharmaceuticals director Leonard Sank to resign after 18 years By Investing.com - Investing.com Nigeria
Oramed Pharmaceuticals director Leonard Sank to resign after 18 years - Investing.com
Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation - TipRanks
Oramed Pharmaceuticals completes $28.5 million warrant repurchase by Scilex - Investing.com Nigeria
Oramed Pharm Completes Warrant Sale, Boosting Liquidity - TipRanks
Oramed Pharmaceuticals Completes Warrant Repurchase with Scilex - TradingView — Track All Markets
Scilex Holding completes $27 million repurchase of warrants from Oramed By Investing.com - Investing.com India
Scilex Holding completes $27 million repurchase of warrants from Oramed - Investing.com
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback - Seeking Alpha
Analyst Downgrade: Will Oramed Pharmaceuticals Inc stock outperform value stocksRate Hike & Daily Market Momentum Tracking - moha.gov.vn
Total debt per share of Oramed Pharmaceuticals Incorporated – TRADEGATE:OJU1 - TradingView — Track All Markets
Aug Swings: Will Oramed Pharmaceuticals Inc stock outperform value stocksWeekly Stock Analysis & Expert Verified Stock Movement Alerts - moha.gov.vn
Oramed Pharmaceuticals (FRA:OJU1) EV-to-OCF : 1.41 (As of Dec. 19, 2025) - GuruFocus
Will Oramed Pharmaceuticals Inc. stock maintain growth storyQuarterly Trade Review & Target Return Focused Picks - DonanımHaber
Can Oramed Pharmaceuticals Inc. stock withstand economic slowdownProduct Launch & Daily Stock Trend Watchlist - DonanımHaber
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.17%
4.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):